Filing Flows › AbCellera Biologics (ABCL) › Q1 2026 › vs Q1 2025
AbCellera Biologics (ABCL) Q1 2026 vs Q1 2025 (year over year)
AbCellera Biologics's revenue rose $4.1M (+96%) from $4.2M in Q1 2025 to $8.3M in Q1 2026. The biggest changes: Research fees +$4.1M (+100%); Licensing and royalty revenue +$24K (+14%).
AbCellera Biologics, Q1 2026: revenue $8.3M (+96% year over year), operating margin -691.7%, net loss $43.2M, operating cash flow −$33.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Research fees | $8.1M | $4.1M | $4.1M | +100% |
| Licensing and royalty revenue | $191K | $167K | $24K | +14% |
| Revenue | $8.3M | $4.2M | $4.1M | +96% |
| Other income, net | $8.0M | $9.7M | −$1.7M | -18% |
| Income tax benefit | $6.4M | $7.4M | −$991K | -13% |
| Net loss | $43.2M | $45.6M | −$2.5M | -5% |
| Costs & expenses | $65.8M | $66.9M | −$1.1M | -2% |
| Operating costs | $65.8M | $66.9M | −$1.1M | -2% |
| Research & development | $46.7M | $42.5M | $4.2M | +10% |
| Other operating costs | $6.8M | $5.3M | $1.5M | +28% |
| Operating cash sources | $52.4M | $31.7M | $20.7M | +65% |
| Depreciation & amortization | $6.8M | $5.3M | $1.5M | +28% |
| Share-based compensation | $12.0M | $14.8M | −$2.8M | -19% |
| Cash used in operations | $33.5M | $11.6M | $22.0M | +190% |
| Net loss absorbed | $43.2M | $45.6M | −$2.5M | -5% |
| Working capital & other | $9.2M | −$13.9M | $23.2M | — |
Questions
How much did AbCellera Biologics's revenue grow year over year in Q1 2026?
AbCellera Biologics's revenue rose $4.1M (+96%) from $4.2M in Q1 2025 to $8.3M in Q1 2026.
What drove AbCellera Biologics's revenue change in Q1 2026?
Research fees +$4.1M (+100%); Licensing and royalty revenue +$24K (+14%).